Compare Johnson Controls International PLC (JCI) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson Controls International PLC vs Recursion Pharmaceuticals Inc — how do they compare? Johnson Controls International PLC trades at $140 (market cap $85.03B), while Recursion Pharmaceuticals Inc trades at $3.08 (market cap $1.53B). The key difference: Johnson Controls International PLC is far larger — about 55.6× Recursion Pharmaceuticals Inc's market cap, and Johnson Controls International PLC pays a 1.15% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| JCI | RXRX | |
|---|---|---|
Market Cap | $85.03B | $1.53B |
Sector | Industrials | Health |
52-Week High | $148.21 | $6.79 |
52-Week Low | $103.24 | $2.84 |
Enterprise Value | $93.86B | $946.50M |
Dividend Yield | 1.15% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
